
SYNLOGIC, INC.
93
Recent developments include Synlogic securing a $1 million subcontract under the Air Force Research Lab and continued analyst coverage with buy recommendations. The company reported a net loss and no revenue for the latest quarter, maintaining strong liquidity ratios.
- Synlogic secured a $1 million subcontract under the Air Force Research Lab, indicating ongoing government collaboration and funding support [N1].
- The company reported a net loss of $3.872 million and no revenue for the quarter ended September 30, 2026, with EPS of -$0.31 per share [S2].
- As of September 30, 2026, Synlogic held $11.56 million in cash and cash equivalents and had a current ratio of 7.06, reflecting strong liquidity [S2].
- Analyst firms have issued buy recommendations on Synlogic, reflecting positive market interest [N1].
Synlogic, Inc. operates in the biopharmaceutical sector with a focus on developing novel therapeutic approaches. The company is incorporated in Delaware and headquartered in Winchester, Massachusetts. Synlogic's governance structure includes a four-member Board of Directors with expertise in life sciences, finance, and corporate development. The company is classified as a small reporting company and non-accelerated filer. Synlogic's common stock is currently not listed on Nasdaq but the Board maintains adherence to Nasdaq governance guidelines. Financially, Synlogic reported no revenue and a net loss for the latest quarter, with a strong liquidity position supported by cash and current assets significantly exceeding current liabilities. The company has secured government subcontract funding and maintains analyst interest in its prospects.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Synlogic, Inc. is a Delaware-incorporated biopharmaceutical company with detailed governance disclosures and a Board of Directors comprising experienced industry professionals. The company reported no revenue and a net loss of $3.872 million for the quarter ended September 30, 2026, with strong liquidity ratios indicating a solid cash position. Synlogic's common stock is no longer listed on Nasdaq but governance practices continue to align with Nasdaq standards. Recent news highlights include a $1 million subcontract award under the Air Force Research Lab and ongoing analyst coverage with buy recommendations [S1][S2][N1][N7].
Synlogic benefits from a strong cash position and liquidity, enabling continued investment in its therapeutic pipeline and research collaborations. The company's governance structure and experienced Board provide strategic oversight and industry insight. Recent government subcontract awards demonstrate external validation of its technology platform. Continued analyst coverage and buy recommendations reflect market interest in Synlogic's potential. If clinical development milestones are achieved, Synlogic could leverage its platform to advance novel therapies in the biopharmaceutical sector.
Synlogic currently reports no revenue and incurs net losses, reflecting the typical risks of clinical-stage biopharmaceutical companies. The absence of Nasdaq listing may impact liquidity and investor access. The company's future depends on successful clinical trials and regulatory approvals, which carry significant scientific and regulatory risks. Market competition and the need for additional capital to fund operations pose ongoing challenges. Failure to achieve key development milestones or secure partnerships could adversely affect the company's prospects.
Synlogic's moat is primarily based on its proprietary biopharmaceutical technology platform and its strategic collaborations, including government research contracts such as the subcontract under the Air Force Research Lab. The company's experienced Board and management team bring significant industry expertise and connections, which support its development pipeline and potential partnerships. However, as a clinical-stage biopharmaceutical company with no current revenue, its competitive advantage depends on successful clinical development and regulatory approvals, which are inherently uncertain.
• Clinical and Regulatory Risk: Synlogic's success depends on the outcome of clinical trials and obtaining regulatory approvals, which are uncertain and may delay or prevent commercialization.
• Financial Risk: The company currently has no revenue and incurs losses, requiring sufficient capital to fund operations and development activities.
• Market and Listing Risk: Synlogic's common stock is no longer listed on Nasdaq, which may affect liquidity and investor perception.
• Operational Risk: Dependence on key personnel and the ability to execute strategic plans and collaborations are critical to Synlogic's progress.
Business trends: Continued focus on therapeutic development supported by government collaborations and analyst interest.
Execution milestones: Advancement of clinical programs and securing strategic partnerships or funding.
Key risks: Clinical trial outcomes, regulatory approvals, financial sustainability, and market liquidity challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Synlogic, Inc. is a publicly reporting company with SEC filings including an amended 10-K for fiscal year ended December 31, 2025, and a 10-Q for the quarter ended September 30, 2026 [S1][S2].
- The company is incorporated in Delaware and has its principal executive offices in Winchester, MA [S1].
- As of March 31, 2026, Synlogic had 11,698,919 shares of common stock outstanding [S1].
- Synlogic's Board of Directors consists of four members with detailed biographies and qualifications disclosed, including Chairman Peter Barrett, Ph.D., and directors James Flynn, Edward Mathers, and Richard P. Shea [S1].
- The Board includes independent directors and has established Audit and Compensation Committees with defined roles and responsibilities [S1].
- Synlogic reported no revenue for the quarter ended September 30, 2026, with a net loss of $3.872 million and basic and diluted EPS of -$0.31 per share [S2].
- As of September 30, 2026, Synlogic held $11.56 million in cash and cash equivalents and had current assets of $11.799 million against current liabilities of $1.671 million, resulting in a current ratio of 7.06 and a cash ratio of 65.94, indicating strong liquidity [S2].
- The company is classified as a non-accelerated filer and a small reporting company [S1].
- Synlogic's common stock is no longer listed on Nasdaq but the Board continues to refer to Nasdaq listing guidelines for governance [S1].
- Recent news includes Synlogic securing a $1 million subcontract under the Air Force Research Lab and multiple analyst coverage and buy recommendations [N1][N7].
Generated 2026-11-15
- S1 | 2026-04-30 | 10-K/A
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-15 | www.nasdaq.com | Summit Therapeutics: FDA Rejects Ivonescimab BLA For EGFR-mutated NSCLC | https://www.nasdaq.com/articles/summit-therapeutics-fda-rejects-ivonescimab-bla-egfr-mutated-nsclc
- N2 | 2026-11-15 | www.nasdaq.com | Microsoft Ignite Starts Nov. 17. Will Microsoft Update Its Paid Copilot Seat Count? | https://www.nasdaq.com/articles/microsoft-ignite-starts-nov-17-will-microsoft-update-its-paid-copilot-seat-count
- N3 | 2026-11-15 | www.nasdaq.com | Is Credo Technology a Better AI Networking Buy Than Broadcom? | https://www.nasdaq.com/articles/credo-technology-better-ai-networking-buy-broadcom
- N4 | 2026-11-15 | www.nasdaq.com | Cameco's CEO Says AI Isn't the Reason to Own Nuclear. Here's What He Says It Is. | https://www.nasdaq.com/articles/camecos-ceo-says-ai-isnt-reason-own-nuclear-heres-what-he-says-it
- N5 | 2026-11-15 | www.nasdaq.com | These 4 Waste and Services Stocks Collect Recurring Revenue | https://www.nasdaq.com/articles/these-4-waste-and-services-stocks-collect-recurring-revenue
- N6 | 2026-11-15 | www.nasdaq.com | 3 Magnificent AI Stocks That Could Help You Make a Fortune | https://www.nasdaq.com/articles/3-magnificent-ai-stocks-could-help-you-make-fortune
- N7 | 2026-05-20 | www.nasdaq.com | Experian FY26 Profit Rises | https://www.nasdaq.com/articles/experian-fy26-profit-rises
- N8 | 2026-05-20 | www.nasdaq.com | Stocks Settle Lower on Rising Bond Yields | https://www.nasdaq.com/articles/stocks-settle-lower-rising-bond-yields
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


